Skip to content

HILT vs ESWT in Supraspinatus Tendinitis

Comparative Effectiveness of High-Intensity Laser Therapy Versus Extracorporeal Shock Wave Therapy in Patients With Supraspinatus Tendinitis

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07615920
Enrollment
48
Registered
2026-05-29
Start date
2026-08-01
Completion date
2027-12-30
Last updated
2026-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Supraspinatus Tendinitis

Brief summary

This randomized controlled trial aims to compare the effectiveness of High-Intensity Laser Therapy (HILT) and Extracorporeal Shock Wave Therapy (ESWT) in patients with supraspinatus tendinitis.

Interventions

High-Intensity Laser Therapy (HILT) is an advanced electrotherapy modality that uses high-power laser energy to penetrate deep musculoskeletal tissues and stimulate biological healing processes. The device emits laser wavelengths ranging between 808-1064 nm with high peak power output, allowing deeper tissue penetration compared to conventional low-level laser therapy. HILT provides analgesic, anti-inflammatory, and biostimulatory effects through increasing local blood circulation, enhancing cellular metabolism, stimulating collagen synthesis, and promoting tissue regeneration. The treatment is non-invasive, safe, and commonly used in musculoskeletal rehabilitation, particularly for tendinopathies and chronic pain conditions.

DEVICEExtracorporeal Shock Wave Therapy

Extracorporeal Shock Wave Therapy (ESWT) is a non-invasive therapeutic modality that delivers high-energy acoustic waves to injured musculoskeletal tissues. The device generates focused or radial shock waves that stimulate tissue healing, neovascularization, pain reduction, and cellular repair mechanisms. ESWT is widely used in the management of tendinopathies, calcific disorders, and chronic musculoskeletal pain. Treatment parameters typically include energy flux density, frequency, number of impulses, and treatment sessions. The therapy is considered safe and effective, with minimal side effects

OTHERConventional Physical Therapy

The conventional physical therapy program consisted of a combination of therapeutic exercises and physical therapy modalities aimed at reducing pain, improving shoulder range of motion, enhancing muscle strength, and restoring functional performance. The program included hot pack application, Transcutaneous Electrical Nerve Stimulation (TENS), stretching exercises, range of motion exercises, strengthening exercises for the rotator cuff and scapular stabilizers, as well as a home exercise program. Treatment sessions were conducted three times per week according to the patient's tolerance and clinical condition

Sponsors

Kafrelsheikh University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Male and female participants aged between 18 and 60 years. * Clinically diagnosed supraspinatus tendinitis confirmed by ultrasound imaging. * Shoulder pain duration greater than 3 months. * Ability to understand and follow study instructions. * Willingness to participate and provide informed consent.

Exclusion criteria

* Full-thickness rotator cuff tear. * Previous shoulder surgery. * Pregnancy. * Neurological disorders affecting the upper limb. * Corticosteroid injection within the previous 3 months. * Shoulder fracture or dislocation. * Systemic inflammatory diseases. * Participation in other physical therapy programs during the study period

Design outcomes

Primary

MeasureTime frameDescription
Pain intensity measured using Visual Analogue Scale (VAS).At baseline and immediately after 4 weeks of interventionPain intensity will be assessed using the Visual Analogue Scale (VAS), where 0 indicates no pain and 10 indicates worst imaginable pain.

Secondary

MeasureTime frameDescription
Shoulder Pain and Disability Measured by the Shoulder Pain and Disability Index (SPADI)At baseline and immediately after 4 weeks of interventionShoulder pain and disability will be assessed using the Shoulder Pain and Disability Index (SPADI). The SPADI score ranges from 0 to 100, with higher scores indicating greater pain and disability.
Upper Extremity Function Measured by the Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH)Time Frame: Baseline and immediately after 4 weeks of intervention.Upper extremity function will be assessed using the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire. DASH scores range from 0 to 100, with higher scores indicating greater disability.
Shoulder Range of Motion Measured Using a Digital GoniometerBaseline and immediately after 4 weeks of intervention.Shoulder range of motion (flexion, abduction, and external rotation) will be measured in degrees using a digital goniometer. Higher values indicate greater shoulder mobility.
Quality of Life Measured by the Short Form-36 Health Survey (SF-36)Baseline and immediately after 4 weeks of intervention.Quality of life will be assessed using the Short Form-36 Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating better health-related quality of life.

Contacts

CONTACTSAMI ABDU AKKUR, MASTER
pt.sami558@gmail.com+966500433558
STUDY_DIRECTORYasmin Mohamed Mahmoud

Kafrelsheikh University Faculty of Physical Therapy Department of Basic Sciences for Physical Therapy

STUDY_CHAIRMahmoud Mohamed Ewida, PHD

Kafrelsheikh University Faculty of Physical Therapy Department of Basic Sciences for Physical Therapy

STUDY_DIRECTORShaimaa Ramadan Eldeab, PHD

Kafrelsheikh University Faculty of Physical Therapy Department of Basic Sciences for Physical Therapy

PRINCIPAL_INVESTIGATORSami ABDU Akkur, MASTER DEGREE STUDENT

Kafrelsheikh University Faculty of Physical Therapy Department of Basic Sciences for Physical Therapy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 30, 2026